0 evaluări0% au considerat acest document util (0 voturi)
38 vizualizări7 pagini
Myocardial Infarction - Pipeline Review, H2 2015 Summary Global Markets Direct s, Myocardial Infarction - Pipeline Review, H2 2015, provides an overview of the Myocardial Infarctions therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by
Myocardial Infarction - Pipeline Review, H2 2015 Summary Global Markets Direct s, Myocardial Infarction - Pipeline Review, H2 2015, provides an overview of the Myocardial Infarctions therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by
Myocardial Infarction - Pipeline Review, H2 2015 Summary Global Markets Direct s, Myocardial Infarction - Pipeline Review, H2 2015, provides an overview of the Myocardial Infarctions therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by
Myocardial Infarction - Pipeline Review, H2 2015 Summary Global Markets Direct s, Myocardial Infarction Pipeline Review, H2 2015 , provides an overview of the Myocardial Infarction s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on latestage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124186/myocardial-infarction-pipeline-review-h2-2015
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124186/myocardial-infarction-pipeline-review-h2-2015
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage
10 Myocardial Infarction Overview
11 Therapeutics Development 12 Pipeline Products for Myocardial Infarction - Overview 12 Pipeline Products for Myocardial Infarction - Comparative Analysis 13 Myocardial Infarction - Therapeutics under Development by Companies 14 Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 20 Myocardial Infarction - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Myocardial Infarction - Products under Development by Companies 25 Myocardial Infarction - Products under Investigation by Universities/Institutes 31 Myocardial Infarction Companies Involved in Therapeutics Development 33 Alligator Bioscience AB 33 Amarantus Bioscience Holdings, Inc. 34 Angion Biomedica Corp. 35 Aprogen, Inc. 36 APT Therapeutics, Inc. 37 AstraZeneca Plc 38 Athersys, Inc. 39 Bayer AG 40 Bharat Biotech International Limited 41 BioLineRx, Ltd. 42 Biscayne Pharmaceuticals, Inc. 43 CellProthera 44 Celyad 45 ChemoCentryx, Inc. 46 Compugen Ltd. 47 CSL Limited 48 FibroGen, Inc. 49 Fina Biotech 50 Hadasit Medical Research Services & Development Ltd 51 Human Stem Cells Institute 52 HUYA Bioscience International, LLC 53 Immune Pharmaceuticals Inc.
54 Inbiopro Solutions Pvt. Ltd.
55 Juventas Therapeutics, Inc. 56 Laboratoires Pierre Fabre SA 57 Lacer, S.A. 58 Lee's Pharmaceutical Holdings Limited 59 LegoChem Biosciences, Inc 60 LG Life Sciences, Ltd. 61 Medestea Research & Production S.p.A. 62 Mesoblast Limited 63 miRagen Therapeutics, Inc. 64 NeuroVive Pharmaceutical AB 65 Omeros Corporation 66 Omni Bio Pharmaceutical Inc. 67 Otsuka Holdings Co., Ltd. 68 Polyphor Ltd. 69 Quantum Genomics SA 70 Recardio GmbH 71 Remedy Pharmaceuticals, Inc. 72 Serodus ASA 73 STELIS Biopharma Pvt. Ltd. 74 Stemedica Cell Technologies, Inc. 75 Stempeutics Research Private Limited 76 TaiGen Biotechnology Co., Ltd. 77 Targazyme, Inc. 78 The International Biotechnology Center (IBC) Generium 79 TiGenix NV 80 Vicore Pharma AB 81 Virocan Therapeutics Private Limited 82 Yuyu Pharma, Inc. 83 Zealand Pharma A/S 84 Zydus Cadila Healthcare Limited 85 Myocardial Infarction - Therapeutics Assessment 86 Assessment by Monotherapy Products 86 Assessment by Target 87 Assessment by Mechanism of Action 91 Assessment by Route of Administration 94 Assessment by Molecule Type 96 Drug Profiles 98 ADC-1004 - Drug Profile 98 Alda-1 - Drug Profile 99 Alpha-1 Antitrypsin - Drug Profile 100 alteplase biosimilar - Drug Profile 102 AMRS-001 - Drug Profile 103 AmVimi-007 - Drug Profile
105 ANG-4011 - Drug Profile
106 AP-102 - Drug Profile 107 APT-102 - Drug Profile 108 balixafortide - Drug Profile 110 Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction - Drug Profile 111 Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile 112 BIS-5409 - Drug Profile 113 Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases - Drug Profile 114 burixafor - Drug Profile 116 C-21 - Drug Profile 118 C3BSGQR-3 - Drug Profile 120 C3BSGQR-4 - Drug Profile 121 CAP-1001 - Drug Profile 122 CAP-1002 - Drug Profile 123 CCX-872 - Drug Profile 125 cenderitide - Drug Profile 126 CGEN-856 - Drug Profile 128 CGEN-856S - Drug Profile 129 CIGB-500 - Drug Profile 131 CM-1 - Drug Profile 132 Cryocell - Drug Profile 134 CSL-112 - Drug Profile 135 CTX-101 - Drug Profile 137 CTX-201 - Drug Profile 139 cyclosporine - Drug Profile 140 danegaptide - Drug Profile 141 Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile 142 Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile 143 dutogliptin tartrate - Drug Profile 144 Ephrin A-1 for Myocardial Infarction - Drug Profile 146 F-573 - Drug Profile 147 Fc-Alpha-1 Antitrypsin - Drug Profile 148 FcAAT-2 - Drug Profile 149 FcAAT-3 - Drug Profile 150 FG-6874 - Drug Profile
151 Gemacell - Drug Profile
152 Gene Therapy for Acute Myocardial Infarction - Drug Profile 153 glyburide - Drug Profile 154 HBI-3802 - Drug Profile 156 HYPER-IL-6 - Drug Profile 157 IBPB-005ET - Drug Profile 158 ICG-001 - Drug Profile 159 IS-20 - Drug Profile 160 JI-38 - Drug Profile 161 JVS-100 - Drug Profile 162 JVS-200 - Drug Profile 164 KR-33028 - Drug Profile 165 LA-8045 - Drug Profile 166 LC-280126 - Drug Profile 167 Mesenchymal Stem Cells - Drug Profile 169 MGN-1374 - Drug Profile 171 MGN-6114 - Drug Profile 172 Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile 173 MPC-150IM - Drug Profile 174 MPC-25IC - Drug Profile 176 MTP-131 - Drug Profile 177 MultiStem - Drug Profile 179 NVP-019 - Drug Profile 183 Oligonucleotide for Oncology and Cardiovascular - Drug Profile 184 Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile 185 OMS-721 - Drug Profile 186 OPC-28326 - Drug Profile 188 Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 190 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 191 Polyglactin 370 for Acute Myocardial Infarction - Drug Profile 192 Protein for Cardiovascular Diseases - Drug Profile 193 ProtheraCytes - Drug Profile 194 QGC-101 - Drug Profile
196 RBB-001 - Drug Profile
197 Recombinant Protein for Myocardial Infarction - Drug Profile 198 Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile 199 Recombinant Prourokinase - Drug Profile 200 remestemcel-L - Drug Profile 201 rivaroxaban - Drug Profile 204 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile 209 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile 210 SBL-004 - Drug Profile 211 SER-130 - Drug Profile 212 Small Molecule for Myocardial Infarction - Drug Profile 213 Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 214 Small Molecules for Myocardial Infarction and Inflammation - Drug Profile 215 Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile 216 Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile 217 Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 218 Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 219 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 220 Stem Cell Therapy for Myocardial Infarction - Drug Profile 221 Stem Cells for Acute Myocardial Infarction - Drug Profile 223 Stempeucel - Drug Profile 224 Synthetic Peptide for Cardiovascular Diseases - Drug Profile 227 THR-100 - Drug Profile 228 ticagrelor - Drug Profile 230 TZ-101 - Drug Profile 234 VN-100 - Drug Profile 236 ZK-001 - Drug Profile 237 Myocardial Infarction - Recent Pipeline Updates 239 Myocardial Infarction - Dormant Projects 308 Myocardial Infarction - Discontinued Products 315 Myocardial Infarction - Product Development Milestones 316 Featured News & Press Releases 316 Appendix 325 Methodology 325 Coverage 325 Secondary Research
325 Primary Research
325 Expert Panel Validation 325 Contact Us 325 Disclaimer Read More @ http://www.idatainsights.com/reports-landing-page.php?id=124186/myocardial-infarction-pipelinereview-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.